Q. Xie

Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer

H. Deng, Q. Li, Q. Xie, 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Number 10 March 14 , 2021 ABOUT COVER

Q. Xie, 2021 .

Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer

Jing Chen, Y. Guan, Baocheng Wang, 2023, Frontiers in Immunology.

Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities

Xueying Zhang, Yanyun Li, Ziyu Ye, 2021, Frontiers in Immunology.

Comparison of nomogram with random survival forest for prediction of survival in patients with spindle cell carcinoma

Zhaohui Du, Q. Xie, Jing Liang, 2022, Journal of cancer research and therapeutics.

Efficacy and safety of apatinib in refractory unresectable and metastatic cholangiocarcinoma: A retrospective analysis.

H. Mou, Ying-Hsun Wu, Lan-fang Yu, 2018 .

Identification of a prognostic immune‐related signature for small cell lung cancer

Hui Yu, Hui-li Chu, Y. Guan, 2021, Cancer medicine.

1022P A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed first line treatment

Q. Liu, M. Kang, C. Zhou, 2022, Annals of Oncology.